Germany's CureVac is on track to file for European approval of its COVID-19 vaccine as early as this month because high infection rates among trial participants are bringing a read-out on efficacy within closer reach. "The cases are coming in fast," Chief Executive Franz-Werner Haas told Reuters. Since starting out in 2000, the biotech firm has focused on so-called messenger RNA (mRNA), a drug and vaccine technology that has also become the recent focus of the European union's procurement negotiations.